What is Liraglutide?
Liraglutide is an incretin medicine with distinct diabetes and weight-management product contexts. Its benefits should be tied to the exact indication and population.
Biological role or research focus
Incretin signaling, glucose control, and appetite.
Victoza and Saxenda have distinct product contexts; verify the actual prescription label.
Role reference: MedlinePlus · Liraglutide ↗
Names you may encounter
Saxenda · Victoza
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GLP-1 receptor agonist
- Main research area
- Glucose, appetite, and cardiovascular outcomes
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Liraglutide ↗
Quick answers
- Is Liraglutide FDA approved?
- Yes. Victoza (NDA 022341) for type 2 diabetes, Saxenda (NDA 206321) for chronic weight management, and Xultophy (with insulin degludec). Source ↗
- Is Liraglutide safe?
- Approved GLP-1 drug for type 2 diabetes and weight management; stomach side effects are common, and it carries a boxed warning about thyroid tumors seen in rodents. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Liraglutide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Liraglutide?
- Yes. Our records list 2 FDA actions naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| LEADER (2016) | Human randomized trial | 9,340 adults with type 2 diabetes and high cardiovascular risk. |
| SCALE Obesity and Prediabetes (2015) | Human randomized trial | 3,731 adults with obesity, or overweight with dyslipidemia or hypertension; 61.2% had prediabetes. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2016
LEADER
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Population / model
- 9,340 adults with type 2 diabetes and high cardiovascular risk.
- Study design
- Liraglutide versus placebo added to standard care; median follow-up 3.8 years.
- Main finding
- The cardiovascular composite occurred in 13.0% versus 14.9%; hazard ratio 0.87 (95% CI 0.78–0.97). Gastrointestinal events were the commonest reason for stopping treatment.
- Limits & context
- The 1.9-percentage-point difference describes this population and follow-up. This was not a trial of otherwise healthy people or the separate weight-management product indication.
Source: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. ↗
Human randomized trial · 2015
SCALE Obesity and Prediabetes
Did weight change in adults without type 2 diabetes?
- Population / model
- 3,731 adults with obesity, or overweight with dyslipidemia or hypertension; 61.2% had prediabetes.
- Study design
- 56-week double-blind placebo comparison with lifestyle counseling in both groups.
- Main finding
- Mean weight reduction was 8.4 kg versus 2.8 kg. At least 5% weight loss occurred in 63.2% versus 27.1%. Nausea and diarrhea were common; serious events occurred in 6.2% versus 5.0%.
- How to read it
- This evaluates weight management, whereas LEADER evaluates cardiovascular events in diabetes.
- Limits & context
- The analysis used last-observation-carried-forward imputation. Trial regimen, population, and duration differ from other GLP-1 trials, preventing simple cross-trial rankings. Funded by Novo Nordisk.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
64 registered studies name Liraglutide as an intervention among the 100 most recently updated of 522 search results; 22 are recruiting or under way, 2 have not started recruiting yet, 31 completed and 9 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 64 listed studies.
Search additional PubMed records ↗Risks & interactions
Approved GLP-1 drug for type 2 diabetes and weight management; stomach side effects are common, and it carries a boxed warning about thyroid tumors seen in rodents.
Thyroid C-cell tumors: liraglutide caused thyroid C-cell tumors in rats and mice, and it is unknown whether it does so in humans. Do not use with a personal or family history of medullary thyroid cancer or MEN 2.
This entry follows the Saxenda (weight management) label; the diabetes product Victoza has a separate label with the same boxed warning. Evidence includes large controlled trials and postmarketing reports, including rare thyroid cancer cases with an uncertain link.
Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Past serious allergic reaction to liraglutide or any ingredient
- Not recommended with severe gastroparesis (label warning)
- Pregnancy, when used for weight loss: no benefit and possible fetal harm
Interactions
- Insulin or sulfonylureas: higher risk of low blood sugar
- Oral medicines: slowed stomach emptying may affect absorption
Serious risks
- Acute pancreatitis
- Gallbladder disease such as gallstones
- Increased heart rate
- Severe gut side effects; kidney injury from dehydration
- Serious allergic reactions, including anaphylaxis and angioedema
- Inhaling stomach contents during anesthesia or deep sedation
Common side effects
- nausea
- diarrhea
- constipation
- vomiting
- injection-site reactions
- headache
- low blood sugar
- indigestion
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Saxenda (liraglutide) prescribing information ↗
Key precautions
Gastrointestinal symptoms, pancreatitis, gallbladder problems, and dehydration are relevant. Thyroid-tumor warnings and increased hypoglycemia risk with certain diabetes medicines require label-specific review.
Source: MedlinePlus · Liraglutide ↗
Regulatory status
- U.S. FDA approval
- Approved
Victoza (NDA 022341) for type 2 diabetes, Saxenda (NDA 206321) for chronic weight management, and Xultophy (with insulin degludec). Generic liraglutide is approved. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
FDA actions
- FDA proposed excluding liraglutide (with semaglutide and tirzepatide) from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk. (2026-04-30) source
- FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source
Other notes
- Liraglutide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The medication reference covers diabetes control, cardiovascular-risk reduction in selected adults with diabetes, and weight management in eligible patients. Victoza and Saxenda are not interchangeable indications.
Source: MedlinePlus · Liraglutide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
Mechanism & research rationale
It supports glucose-dependent insulin release and slows stomach emptying. Appetite and weight changes are related effects, while cardiovascular outcomes require dedicated trials.
Source: MedlinePlus · Liraglutide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Victoza and Saxenda have distinct product contexts; verify the actual prescription label.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Was LEADER a general weight-loss study?
No. It studied cardiovascular outcomes in people with diabetes and high cardiovascular risk.
Source: MedlinePlus · Liraglutide ↗
Does the same molecule imply the same product instructions?
No. Brand, indication, formulation, and prescribing instructions still matter.
Source: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. ↗
References & editorial record
- MedlinePlus · Liraglutide ↗
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. ↗
- SCALE Obesity and Prediabetes · 2015 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Semaglutide and NAION: the FDA’s new vision warning, in numbers
On November 9, 2026 the FDA required every GLP-1 medicine, including semaglutide (Ozempic, Wegovy, Rybelsus), to carry a warning about NAION, a rare optic-nerve condition. How rare it is, where the concern came from, how strong the evidence is, and which symptoms need a same-day call.
Read the guide →RESEARCH FIELD GUIDE
What happens when you stop semaglutide? What the trials show
In the trials, most people who stopped semaglutide (Ozempic, Wegovy) regained much of the weight within a year, and gains in blood pressure and blood sugar faded too. The numbers from STEP 1, STEP 4 and tirzepatide’s SURMOUNT-4, and what the evidence says may help.
Read the guide →

